Abstract:Severe asthma is a complex and heterogeneous clinical condition presented as chronic inflammation of the airways. Conventional treatments are mainly focused on symptom control; however, there has been a shift towards personalized medicine. Identification of different phenotypes driven by complex pathobiological mechanisms (endotypes), especially those driven by type-2 (T2) inflammation, has led to improved treatment outcomes. Combining biomarkers with T2-targeting monoclonal antibodies is crucial for developing personalized treatment strategies. Several biological agents, including anti-immunoglobulin E, anti-interleukin-5, and anti-thymic stromal lymphopoietin/interleukin-4, have been approved for the treatment of severe asthma. These biological therapies have demonstrated efficacy in reducing asthma exacerbations, lowering eosinophil count, improving lung function, diminishing oral corticosteroid use, and improving the quality of life in selected patients. Severe asthma management is undergoing a profound transformation with the introduction of ongoing and future biological therapies. The availability of novel treatment options has facilitated the adoption of phenotype/endotype-specific approaches and disappearance of generic interventions. The transition towards precision medicine plays a crucial role in meticulously addressing the individual traits of asthma pathobiology. An era of tailored strategies has emerged, allowing for the successful targeting of immune-inflammatory responses that underlie uncontrolled T2-high asthma. These personalized approaches hold great promise for improving the overall efficacy and outcomes in the management of severe asthma. This article comprehensively reviews currently available biological agents and biomarkers for treating severe asthma. With the expanding repertoire of therapeutic options, it is becoming increasingly crucial to comprehend the influencing factors, understand the pathogenesis, and track treatment progress in severe asthma.

Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes

Immunologic aspects of asthma: from molecular mechanisms to disease pathophysiology and clinical translation

Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease

Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease

Epigenetic Approaches to Identifying Asthma Endotypes

Current Understanding of Asthma Pathogenesis and Biomarkers

The understanding of asthma pathogenesis in the era of precision medicine

Pediatric asthma and development of atopy

Approaches to studying the pathogenesis of asthma

Biologic Medications for Severe Asthma: Implications for Understanding Pathogenic Heterogeneity and Endotypes

Current Understanding on Molecular Perspectives

Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons

Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation

A Current Perspective of Allergic Asthma: From Mechanisms to Management

From Biomarkers to Biologics

Personalized asthma management in pediatric patients based on treatment response

New insights into asthma pathogenesis and treatment

Biomarkers in asthma, potential for therapeutic intervention

Role of Epigenetics in the Pathogenesis, Treatment, Prediction, and Cellular Transformation of Asthma